In Segment C, individuals will obtain ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually disease progression or the participants are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit solutions within three times before the main https://davidc085heb9.wikipublicist.com/user